Jun 18, 2024, 03:30
Ruben Mesa: Most active combination for MF to date
Ruben Mesa shared on LinkedIn:
“Honored to be a Co-Investigator of important Pelabresib plus RUX 1L vs RUX Phase III trial presented as dual abstracts at EHA2024 by Raajit Rampal demonstrating impact of PELA/RUX on fibrosis, erythroid progenitors, VAF, splenomegaly and most symptoms. Most active combination for MF to date!”
Source: Ruben Mesa/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 23, 2024, 03:08
Oct 23, 2024, 02:59
Oct 23, 2024, 02:53
Oct 23, 2024, 02:46
Oct 23, 2024, 00:05
Oct 22, 2024, 23:59
Oct 22, 2024, 23:53